Applications of proteomics in the study of inflammatory bowel diseases: Current status and future directions with available technologies

Philip Alex, Marjan Gucek, Xuhang Li

Research output: Contribution to journalArticle

Abstract

Inflammatory bowel diseases (IBD) are chronic, heterogeneous, and multifactorial intestinal inflammatory disorders. Major challenges in IBD research include identification of major pathogenic alterations of genes/proteins as well as effective biomarkers for early diagnosis, prognosis, and prediction of therapeutic response. Since proteins govern cellular structure and biological function, a wide selection of proteomic approaches enables effective characterization of IBD pathogenesis by investigating the dynamic nature of protein expression, cellular and subcellular distribution, posttranslational modifications, and interactions at both the cellular and subcellular levels. The aims of this review are to 1) highlight the current status of proteomic studies of IBD, and 2) introduce the available and emerging proteomic technologies that have potential applications in the study of IBD. These technologies include various mass spectrometry technologies, quantitative proteomics (2D-PAGE, ICAT, SILAC, iTRAQ), protein/antibody arrays, and multiepitope-ligand cartography. This review also presents information and methodologies, from sample selection and enrichment to protein identification, that are not only essential but also particularly relevant to IBD research. The potential future application of these technologies is expected to have a significant impact on the discovery of novel biomarkers and key pathogenic factors for IBD.

Original languageEnglish (US)
Pages (from-to)616-629
Number of pages14
JournalInflammatory Bowel Diseases
Volume15
Issue number4
DOIs
StatePublished - 2009

Fingerprint

Inflammatory Bowel Diseases
Proteomics
Technology
Proteins
Biomarkers
Protein Array Analysis
Electrophoresis, Gel, Two-Dimensional
Cellular Structures
Post Translational Protein Processing
Research
Direction compound
Early Diagnosis
Mass Spectrometry
Ligands
Antibodies

Keywords

  • Biomarkers
  • Crohn's disease
  • Inflammatory bowel disease (IBD)
  • Proteomics
  • Ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology
  • Immunology and Allergy

Cite this

Applications of proteomics in the study of inflammatory bowel diseases : Current status and future directions with available technologies. / Alex, Philip; Gucek, Marjan; Li, Xuhang.

In: Inflammatory Bowel Diseases, Vol. 15, No. 4, 2009, p. 616-629.

Research output: Contribution to journalArticle

@article{d1654b1cb6704f45ab04a750324635df,
title = "Applications of proteomics in the study of inflammatory bowel diseases: Current status and future directions with available technologies",
abstract = "Inflammatory bowel diseases (IBD) are chronic, heterogeneous, and multifactorial intestinal inflammatory disorders. Major challenges in IBD research include identification of major pathogenic alterations of genes/proteins as well as effective biomarkers for early diagnosis, prognosis, and prediction of therapeutic response. Since proteins govern cellular structure and biological function, a wide selection of proteomic approaches enables effective characterization of IBD pathogenesis by investigating the dynamic nature of protein expression, cellular and subcellular distribution, posttranslational modifications, and interactions at both the cellular and subcellular levels. The aims of this review are to 1) highlight the current status of proteomic studies of IBD, and 2) introduce the available and emerging proteomic technologies that have potential applications in the study of IBD. These technologies include various mass spectrometry technologies, quantitative proteomics (2D-PAGE, ICAT, SILAC, iTRAQ), protein/antibody arrays, and multiepitope-ligand cartography. This review also presents information and methodologies, from sample selection and enrichment to protein identification, that are not only essential but also particularly relevant to IBD research. The potential future application of these technologies is expected to have a significant impact on the discovery of novel biomarkers and key pathogenic factors for IBD.",
keywords = "Biomarkers, Crohn's disease, Inflammatory bowel disease (IBD), Proteomics, Ulcerative colitis",
author = "Philip Alex and Marjan Gucek and Xuhang Li",
year = "2009",
doi = "10.1002/ibd.20652",
language = "English (US)",
volume = "15",
pages = "616--629",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Applications of proteomics in the study of inflammatory bowel diseases

T2 - Current status and future directions with available technologies

AU - Alex, Philip

AU - Gucek, Marjan

AU - Li, Xuhang

PY - 2009

Y1 - 2009

N2 - Inflammatory bowel diseases (IBD) are chronic, heterogeneous, and multifactorial intestinal inflammatory disorders. Major challenges in IBD research include identification of major pathogenic alterations of genes/proteins as well as effective biomarkers for early diagnosis, prognosis, and prediction of therapeutic response. Since proteins govern cellular structure and biological function, a wide selection of proteomic approaches enables effective characterization of IBD pathogenesis by investigating the dynamic nature of protein expression, cellular and subcellular distribution, posttranslational modifications, and interactions at both the cellular and subcellular levels. The aims of this review are to 1) highlight the current status of proteomic studies of IBD, and 2) introduce the available and emerging proteomic technologies that have potential applications in the study of IBD. These technologies include various mass spectrometry technologies, quantitative proteomics (2D-PAGE, ICAT, SILAC, iTRAQ), protein/antibody arrays, and multiepitope-ligand cartography. This review also presents information and methodologies, from sample selection and enrichment to protein identification, that are not only essential but also particularly relevant to IBD research. The potential future application of these technologies is expected to have a significant impact on the discovery of novel biomarkers and key pathogenic factors for IBD.

AB - Inflammatory bowel diseases (IBD) are chronic, heterogeneous, and multifactorial intestinal inflammatory disorders. Major challenges in IBD research include identification of major pathogenic alterations of genes/proteins as well as effective biomarkers for early diagnosis, prognosis, and prediction of therapeutic response. Since proteins govern cellular structure and biological function, a wide selection of proteomic approaches enables effective characterization of IBD pathogenesis by investigating the dynamic nature of protein expression, cellular and subcellular distribution, posttranslational modifications, and interactions at both the cellular and subcellular levels. The aims of this review are to 1) highlight the current status of proteomic studies of IBD, and 2) introduce the available and emerging proteomic technologies that have potential applications in the study of IBD. These technologies include various mass spectrometry technologies, quantitative proteomics (2D-PAGE, ICAT, SILAC, iTRAQ), protein/antibody arrays, and multiepitope-ligand cartography. This review also presents information and methodologies, from sample selection and enrichment to protein identification, that are not only essential but also particularly relevant to IBD research. The potential future application of these technologies is expected to have a significant impact on the discovery of novel biomarkers and key pathogenic factors for IBD.

KW - Biomarkers

KW - Crohn's disease

KW - Inflammatory bowel disease (IBD)

KW - Proteomics

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=67650189497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650189497&partnerID=8YFLogxK

U2 - 10.1002/ibd.20652

DO - 10.1002/ibd.20652

M3 - Article

C2 - 18844215

AN - SCOPUS:67650189497

VL - 15

SP - 616

EP - 629

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 4

ER -